Results 271 to 280 of about 562,894 (340)
A System dynamics analysis of the factors influencing the promotion of prefabricated decoration, based on a co-occurrence network. [PDF]
PLoS OneWang Y, Liu J, Zhang G, Geng X, Liu Y.
europepmc +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni +3 more
wiley +1 more source
Distribution of government health financing benefits among women who delivered in public institutions in Bangladesh: a nationally representative cross-sectional study. [PDF]
Lancet Reg Health Southeast AsiaRafi MA +5 more
europepmc +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez +5 more
wiley +1 more source
Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy. [PDF]
Front Public HealthWen Y, Wei Y, Liu L.
europepmc +1 more source
Expediting Drug Development in Japan: A PMDA Perspective
Clinical Pharmacology &Therapeutics, EarlyView.Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so‐called “Drug Loss”, which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe
Yoichi Kohno +8 more
wiley +1 more source